Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

So called “double mutant” variants found in India

What is a “double mutant” variant?

Like all viruses, the coronavirus keeps changing in small ways as it passes from one person to another.

The vast majority of these mutations are inconsequential and don’t alter the way the virus behaves.

But some mutations trigger changes in the spike protein that the virus uses to latch on to and enter human cells – these variants could potentially be more infectious, cause more severe disease or evade vaccines.

Vaccines against respiratory pathogens like SARS-Cov2, the virus that causes Covid-19, protect us by stimulating our bodies to make antibodies.

The best type to protect us are the “neutralizing antibodies” because they block the virus from being able to enter the human cells.

Indian genome scientists have detected a so-called “double variant” of the novel coronavirus.

The government said that an analysis of the samples collected from the western state of Maharashtra showed “an increase in the fraction of samples with the E484Q and L452R mutations” compared with December last year.

“Such [double] mutations confer immune escape and increased infectivity,” the health ministry said in a statement.

Dr Jeremy Kamil, a virologist at Louisiana State University Health Sciences Center Shreveport, says the E484Q is similar to E484K – a mutation seen in the B.1.351 (South Africa) and P.1 (Brazil) variants, which have emerged independently several times.

If enough mutations happen in a viral family tree or a lineage, the virus can begin to function differently and the lineage can become a so-called ‘variant of concern’.

As far as the L452R mutation – also found in the “double mutation” in India – it first got attention as part of B.1.427/B.1.429 lineage in the US, which is sometimes called the “California variant”, Dr Kamil told me.

Source: BBC

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!